My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches

Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.

EP. 1: Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors

April 12th 2024

Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.

EP. 2: Targeting RET Fusion in Brain Tumor

April 12th 2024

Dr. Lukas presents a case of a young man with a BRAF-fused brain tumor treated with a MEK inhibitor. Explored tailored therapy targeting the underlying genetic alteration.

EP. 3: BRAF V600E Mutant Ganglioglioma

April 19th 2024

Dr. Schreck brings forward a compelling case of a teenage female with BRAF V600E mutant ganglioglioma. Witness how the identification of this specific genetic alteration paved the way for treated with targeted therapy.

EP. 4: Challenges in Adopting Targeted Therapies for BRAF Alterations

April 19th 2024

Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.

EP. 5: Efficacy and Safety of Tumor Agnostic Therapies

April 26th 2024

Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.

EP. 6: PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers

April 26th 2024

Dr. Subbiah presents a pancreatic cancer case with PRKARA1A- RET fusion treated with selpercatinib in a clinical trial.

EP. 7: Impact and Positioning of Tumor Agnostic Approvals

May 3rd 2024

The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer.

EP. 8: Future Outlook for RET Fusion-Targeted Therapies

May 3rd 2024

The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.